Table 1. Overview of clinical and histopathological parameters for each patient.
| Gender | Age (Years) | Survival (Months) | Histological Subtype | Surgery | Chemotherapy | Response (modRECIST) |
|---|---|---|---|---|---|---|
| M | 70 | 67,43 | E | Decortication | 4 cycles Cisplatin/Pemetrexed 2nd line | SD |
| M | 68 | 72,1 | E | Decortication | 5 cycles Cisplatin/Pemetrexed 2nd line | SD |
| M | 57 | 36,43 | E | Decortication | 6 cycles Cisplatin/Pemetrexed 1st line | SD |
| M | 66 | 28,9 | E | Pleuropneumonectomy | 6 cycles Carboplatin/Pemetrexed 2nd line | PD |
| F | 77 | 34,77 | E | Pleurodesis | 3 cycles Carboplatin/Pemetrexed plus 2 cycles Pemetrexed monotherapy 1st line | SD |
| M | 72 | 21,9 | E | Decortication | 4 cycles Carboplatin/Pemetrexed 1st line | SD |
| M | 59 | 8,93 | E | Pleurodesis | 2 cycles Carbo/Pemetrexed 1st line | PD |
| M | 62 | 7,27 | E | Pleurodesis | 1 cycle Carboplatin/Pemetrexed 1st line | NA |
| M | 62 | 16,6 | E | Decortication | 4 cycles Platin/Pemetrexed 1st line | NA |
| M | 76 | 33,93 | E | Pleurodesis | 6 cycles Carboplatin/Pemetrexed 1st line | SD |
| M | 59 | 7,27 | E | Decortication | 6 cycles Cisplatin/Pemetrexed 1st line | SD |
| M | 82 | 13,5 | E | Pleurodesis | 6 cycles Pemetrexed Monotherapy 1st line | SD |
| M | 70 | 48,83 | E | none | 6 cycles Platin/Pemetrexed 1st line | PR |
| M | 67 | 20,93 | E | none | 4 cycles Carboplatin/Pemetrexed 1st line | PD |
| M | 62 | 35,47 | E | Decortication | 4 cycles Cisplatin/Pemetrexed 1st line | PR |
| M | 49 | 16,1 | E | Pleuropneumonectomy | 4 cycles Cisplatin/Pemetrexed (adjuvant therapy) | NA |
| F | 77 | 81,73 | E | Decortication | 4 cycles Carboplatin/Pemetrexed 1st line und 6 cycles 2nd line | PR |
| M | 68 | 53,33 | E | Decortication | 4 cycles Cisplatin/Pemetrexed 1st line | SD |
| M | 71 | 15,43 | E | Pleurodesis | 1 cycle Carboplatin/Pemetrexed 1st line | PD |
| M | 67 | 16,23 | B | Decortication | 4 cycles Carbo/Pemetrexed 1st line | PD |
| M | 65 | 9,67 | E | Decortication | 2 cycles Carbo/Pemetrexed 1st line | NA |
| M | 67 | 19,13 | E | Pleurodesis | 6 cycles Carbo/Pemetrexed 1st line | SD |
| F | 86 | 27,37 | E | Pleurodesis | 8 cycles Pemetrexed Mono 1st line | PR |
| M | 69 | 15,87 | E | Decortication | 3 cycles Platin/Pemetrexed 1st line | PD |
| F | 63 | 24,53 | E | Decortication | 6 cycles Carbo/Pemetrexed 1st line | PR |
| M | 77 | 62,07 | E | Decortication | 6 cycles Platin/Pemetrexed 1st line | PR |
| F | 73 | 48,9 | E | Decortication | 3 cycles Cisplatin/Pemetrexed 1st line | PD |
| M | 69 | 16,1 | E | Pleuropneumonectomy | 4 cycles Cisplatin/Pemetrexed (adjuvant therapy) | NA |
| F | 64 | 9,07 | E | none | 2 cycles Platin/Pemetrexed 1st line | PD |
| M | 67 | 11,5 | S | Decortication | 6 cycles Cisplatin/Pemetrexed 1st line | SD |
| M | 73 | 5,2 | E | Pleurodesis | 3 cycles Pemetrexed Mono 1st line | NA |
| M | 66 | 12,33 | E | Decortication | 6 cycles Cisplatin/Pemetrexed 1st line | SD |
| M | 67 | 8,53 | S | Decortication | 4 cycles Carbo/Pemetrexed 1st line | PD |
| F | alive | n.n. | E | Pleurodesis | 6 cycles Cisplatin/Pemetrexed 1st Line | PR |
| M | 76 | 22,50 | B | Decortication | 4 cycles Carboplatin/Pemetrexed 1st Line | PR |
| M | 77 | 28,6 | E | Decortication | 4 cycles Cisplatin/Pemetrexed 1st Line | SD |
| M | 71 | 18,77 | E | Decortication | 4 cycles Cisplatin/Pemetrexed 1st Line | SD |
| M | 72 | 40,37 | E | Decortication | 4 cycles Carbo/Pemetrexed 1st Line | SD |
| F | 54 | 10,1 | E | Decortication | 5 cycles Cisplatin/Pemetrexed 1st Line | PD |
| F | 64 | 11,57 | B | Decortication | 4 cycles Cisplatin/Pemetrexed 1st Line | PD |
| M | 81 | 6,33 | B | Decortication | 3 cycles Pemetrexed Mono 1st Line | PD |
| M | 73 | 4,67 | B | Decortication | 1 cycle Carboplatin/Pemetrexed 1st Line | NA |
| M | 69 | 8,13 | B | Pleurodesis | 4 cycles Cisplatin/Pemetrexed 1st Line | PD |
| M | 75 | 15,37 | E | Decortication | 4 cycles Cisplatin/Pemetrexed 1st Line | PR |
| M | 71 | 22,73 | B | Decortication | 6 cycles Cisplatin/Pemetrexed 1st Line | PR |
| M | 61 | 25,63 | E | Decortication | 4 cycles Cisplatin/Pemetrexed 1st Line | SD |
| M | 38 | 37,03 | E | Decortication | 6 cycles Cisplatin/Pemetrexed 1st Line | PR |
| M | 79 | 19,27 | E | Decortication | 6 cycles Carbo/Pemetrexed 1st Line | SD |
| F | 61 | 12,27 | E | Decortication | 5 cycles Cisplatin/Pemetrexed 1st Line | SD |
| M | 74 | 29,03 | E | Decortication | 5 cycles Carbo/Pemetrexed 1st Line | SD |
| F | 79 | 13,77 | S | Decortication | 6 cycles Carbo/Pemetrexed 1st Line | SD |
| F | 64 | 4,03 | E | Decortication | 3 cycles Cisplatin/Pemetrexed 1st Line | PD |
| M | alive | n.n. | E | Decortication | 6 cycles Carbo/Pemetrexed 1st Line | SD |
| M | 71 | 18,13 | E | Decortication | 6 cycles Cisplatin/Pemetrexed 1st Line | SD |
| M | 60 | 13,23 | E | Decortication | 6 cycles Cisplatin/Pemetrexed 1st Line | SD |
| M | 66 | 12,27 | E | Decortication | 6 cycles Cisplatin/Pemetrexed 1st Line | PD |
Patients gender, age at time of diagnosis, overall survival, histological subtype as well as therapeutic strategies and response rate are shown. Response data were evaluated using the modified Response Evaluation Criteria in Solid Tumors (modRECIST).